Cyclic boronic acid ester derivatives and therapeutic uses thereof
Method of treating or ameliorating a bacterial infection comprising administering a composition comprising a cyclic boronic acid ester compound in combination with a carbapenem antibacterial agent such as Biapenem, and the pharmacokinetics studies thereof are provided.
1. A method for treating a bacterial infection in a human, comprising administering to a subject in need thereof a composition comprising Compound I or a pharmaceutically acceptable salt thereof and a carbapenem antibacterial agent to achieve a Compound I plasma clearance from about 0.01 L/h/kg to about 5 L/h/kg, wherein compound I has the structure:
2. The method of claim 1 , wherein the carbapenem antibacterial agent is selected from the group consisting of Imipenem, Biapenem, Doripenem, Meropenem, and Ertapenem.
3. The method of claim 2 , wherein the carbapenem antibacterial agent is Biapenem.
4. The method of claim 1 , wherein Compound I is administered in a dose range from about 0.1 mg/kg to about 1,000 mg/kg of body weight.
5. The method of claim 4 , wherein Compound I is administered in a dose range from about 0.5 mg/kg to about 500 mg/kg of body weight.
6. The method of claim 1 , wherein the Compound I plasma clearance is from about 0.025 L/h/kg to about 2.2 L/h/kg.
7. The method of claim 1 , wherein the Compound I plasma clearance is from about 0.05 L/h/kg to about 1 L/h/kg.
8. The method of claim 1 , wherein the composition is administered intravenously.
9. The method of claim 1 , wherein the infection is caused by a bacteria selected from the group consisting of Pseudomonas aeruginosa, Pseudomonas fluorescens, Stenotrophomonas maltophilia, Escherichia coli, Citrobacter freundii, Salmonella typhimurium, Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae, Klebsiella oxytoca, Serratia marcescens, Acinetobacter calcoaceticus, Acinetobacter haemolyticus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Yersinia intermedia, Haemophilus influenzae, Haemophilus parainfluenzae, Haemophilus haemolyticus, Haemophilus parahaemolyticus, Helicobacter pylori, Campylobacter fetus, Campylobacter jejuni, Campylobacter coli, Vibrio cholerae, Vibrio parahaemolyticus, Legionella pneumophila, Listeria monocytogenes, Neisseria gonorrhoeae, Neisseria meningitidis, Moraxella, Bacteroides fragilis, Bacteroides vulgatus, Bacteroides ovalus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides eggerthii , and Bacteroides splanchnicus.
10. The method of claim 1 , wherein the composition further comprises an additional medicament selected from the group consisting of an antibacterial agent, an antifungal agent, an antiviral agent, an anti-inflammatory agent, and an anti-allergic agent.
11. A method for treating a bacterial infection in a human, comprising administering to a subject in need thereof a composition comprising Compound I or a pharmaceutically acceptable salt thereof and a carbapenem antibacterial agent to achieve a Compound I half-life from about 0.05 hr to about 10 hrs, wherein Compound I has the structure:
12. The method of claim 11 , wherein the carbapenem antibacterial agent is selected from the group consisting of Imipenem, Biapenem, Doripenem, Meropenem, and Ertapenem.
13. The method of claim 12 , wherein the carbapenem antibacterial agent is Biapenem.
14. The method of claim 11 , wherein Compound I is administered in a dose range from about 0.1 mg/kg to about 1,000 mg/kg of body weight.
15. The method of claim 14 , wherein Compound I is administered in a dose range from about 0.5 mg/kg to about 500 mg/kg of body weight.
16. The method of claim 11 , wherein the Compound I half-life is from about 0.1 hr to about 7 hrs.
17. The method of claim 11 , wherein the Compound I half-life is from about 0.3 hr to about 5 hrs.
18. The method of claim 11 , wherein the composition is administered intravenously.
19. The method of claim 11 , wherein the infection is caused by a bacteria selected from the group consisting of Pseudomonas aeruginosa, Pseudomonas fluorescens, Stenotrophomonas maltophilia, Escherichia coli, Citrobacter freundii, Salmonella typhimurium, Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae, Klebsiella oxytoca, Serratia marcescens, Acinetobacter calcoaceticus, Acinetobacter haemolyticus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Yersinia intermedia, Haemophilus influenzae, Haemophilus parainfluenzae, Haemophilus haemolyticus, Haemophilus parahaemolyticus, Helicobacter pylori, Campylobacter fetus, Campylobacter jejuni, Campylobacter coli, Vibrio cholerae, Vibrio parahaemolyticus, Legionella pneumophila, Listeria monocytogenes, Neisseria gonorrhoeae, Neisseria meningitidis, Moraxella, Bacteroides fragilis, Bacteroides vulgatus, Bacteroides ovalus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides eggerthii , and Bacteroides splanchnicus.
20. The method of claim 11 , wherein the composition further comprises an additional medicament selected from the group consisting of an antibacterial agent, an antifungal agent, an antiviral agent, an anti-inflammatory agent, and an anti-allergic agent.